ALPCO Diagnostics inked a distribution deal with biomarker maker BioPorto to distribute the Danish company’s immunoassays in the U.S. and Canada.
Salem, N.H.-based ALPCO, which makes and distributes immunoassay diagnostic products, will sell BioPorto’s portfolio of NGAL acute kidney injury markers.
The deal with BioPorto is the second foreign distribution agreement for ALPCO since the summer. In August, the company signed an agreement with Stratech Scientific to establish a sales channel in the United Kingdom. Under the terms of that deal, the British company will promote ALPCO’s diabetes and obesity product line.